Ahead of the Bell: BioDelivery Sciences soars

July 7, 2014 12:40 PM

14 0

Shares of BioDelivery Sciences International surged Monday before markets opened and after the drug developer said its potential severe pain treatment fared better than a placebo, or fake drug, in another late-stage study.

The Raleigh, North Carolina, company said the trial also triggered another $10 million milestone payment from Endo International Plc, which has a licensing agreement with BioDelivery.

Also read: Opioid makers paid millions to advocacy groups: U.S. Senate report

Read more

To category page